Real World Data
Optimising the use of real world data to drive effective outcomes
Real world evidence (RWE) continues to drive healthcare and research discussions and decisions. ICON delivers Real World Intelligence®, bringing together innovative thinking and technology solutions to identify, generate, and communicate the clinical, safety and cost-effectiveness evidence that regulators, payers and providers demand.
Generate RWE using cross sectional studies and medical chart reviews
Download our white paper, Real World Evidence Generation: The Value of Cross-Sectional Studies and Medical Chart Reviews to learn how this hybrid approach to study design can be advantageous for generating real world evidence. Get insights on the issues you need to consider to ensure that your study is planned to produce robust scientific data that can be extrapolated beyond the study population.
Real World Data blogs and media contributions
-
Media article: Mind the gap: Managed access programmes as an alternative to long-term follow up studies
Veronica Guiterrez Martinez and Michael Tokar at ICON discuss the challenges of setting up MAPs and the various considerations that must be tackled for a successful programme.
-
Media article: The quest for increased efficiency in personalised medicine clinical trials
A thought leadership piece by Lawrence Johnson and Cynthia Spittle discussing personalised medicine and how digital devices can improve treatment across a wide spectrum of conditions.
-
Media article: Planning a managed access programme: Advice for clinical teams
ICON's Veronica Gutierrez Martinez considers how Sponsors need to plan carefully before undertaking a MAP so that they have the resources, processes, and tools in place to support the inevitable demand.
-
.jpg?crop=yes&w=545&h=286&itok=xQGec-95 "RWD-webinar-2-(2)")
Media article: Ask the Experts: Advancing real-world data in the precision medicine era
A panel discussion providing perspectives on the applications, challenges and future of the collection of biospecimens, and how real-world data can be used to advance the field of precision medicine.
-
Media article: Encouraging patient participation in real world studies
Real world data is rapidly becoming the latest frontier for life sciences companies for supporting regulatory filings and conducting drug safety surveillance.
-
Media article: Five common literature reviews for RWE generation
ICON's Alexia Burton, Ram Mishra and Rob Sambrook discuss how having a clear understanding of the purpose, audience, timing and available resources can guide researchers to the most effective approach.
-
.jpg?crop=yes&w=545&h=286&itok=YVLdvoRS "RWD-webinar-4-(2)")
Media article: Risk-Based Monitoring and Real-World Data: A Decentralised Ecosystem
Ian O'Shaughnessy considers how to ensure a reality for the bright future of digitisation as clinical trials evolve.
-
Blog: Harnessing Big Data: The raw material of digital transformation
The integration and mastery of digital technologies is becoming essential to improve the efficiency of clinical trial operations.
.jpg?crop=yes&w=555&h=292&a=0,24&itok=5-iph99p "RWD-webinar-2-(2)"){kind=icon}
.jpg?crop=yes&w=555&h=292&a=0,24&itok=YMaejpS6 "RWD-webinar-4-(2)"){kind=icon}
Real World Data webinars
The landscape of real world data can be difficult to navigate
Database mapping provides a tool to systematically identify and evaluate RWD sources.
Effective ingestion and normalization of real world data sources
As more sources of anonymized Real World Data (RWD) become available, the ability to ingest, standardize and then link the collected disparate data sets is critical to creating insightful, analytical output.
Five common barriers to harmonised real world data (RWD)
Duplicate data environments, redundant data subscriptions, and siloed data access are not providing a good enough return on investment for Real World Evidence (RWE) generation
.jpg?crop=yes&w=555&h=292&a=0,24&itok=ksnQ2MAM "RWD-webinar-2-(2)"){kind=icon}
Optimise your RWE investments
Increasing drug development cost, the shift from volume to value-based pricing, and competition from generics and biosimilars, are forcing pharma and life science organizations are looking towards Real World Evidence (RWE) to prove the value – cost, safety, and effectiveness - of their products.
.jpg?crop=yes&w=555&h=292&a=0,24&itok=f-nEJVS0 "RWD-webinar-4-(2)"){kind=icon}
How RWE continues to shape the late phase research landscape
Creating a comprehensive RWE strategy demands a focus on organizing and synthesizing the many real world data (RWD) asset options that are available to life sciences companies.
Real world evidence across the product lifecycle
Payment models and federal reforms are increasingly focused on the real world impact of treatments and devices. More regulatory guidance is being released in both the US and EU around the use of RWE to support and enhance submissions and product uptake.
Reduce the cost of post-market surveillance with real world data
Real-World Evidence (RWE) is derived from Real World Data (RWD), and early use of Real World Evidence can cut post-marketing study costs and Medical Device time-to-market.
Devices are especially good candidates for early RWE use since evidence collected in the context of actual patient care from previously approved versions or similar devices often can be used to supplement findings from clinical trials of the latest version in development.
RWD and Alzheimer's disease
Real world data such as sleep quality and quantity have clinical relevance in Alzheimer's disease, providing objective measures of sleep and activity patterns that are not subject to patient recall bias. Review the use of wearables in Alzheimer’s disease to provide objective measures of sleep and activity patterns that are not subject to patient recall bias.
Harnessing technology to maximise RWE value
Late phase research is undergoing rapid transformation due to the impact of healthcare digitalisation and the greater availability of and access to Real World Data (RWD).
Meeting evidentiary needs with EHRs
How can the abundance of Real World Data (RWD) from Electronic Health Records (EHRs) enhance your late phase research studies while decreasing study costs?
Receive more insights on Real World Data
Please visit ICON's Preference Centre and select 'Real World Evidence' under 'Topics of Interest' to receive new insights on oncology.